ponatinib
Iclusig (ponatinib) is an oral, multi-targeted kinase inhibitor from Takeda for Philadelphia chromosome-positive leukemias. It blocks the BCR-ABL driver protein in chronic myeloid leukemia and acute lymphoblastic leukemia, including the hard-to-treat T315I mutation, after other kinase inhibitors have failed or are unsuitable.
This page is based on FDA prescribing information and the EMA medicine record for ponatinib, cross-checked with DailyMed, MedlinePlus, and the National Cancer Institute dictionary; the mechanism is explained in plain language, and analogies are used only where they stay accurate.
How it works
Explains what the medicine does in the body, not dosing, side effects, or safety.
An analogy
Philadelphia chromosome-positive leukemia runs on a stuck accelerator, the BCR-ABL protein. Some cancers mutate the accelerator's lock, the T315I change, so earlier drugs no longer fit. Ponatinib is shaped to reach around that lock: it grips both the ordinary and the mutated accelerator and switches the growth signal off, which is why it works when other kinase inhibitors have stopped helping.
In simple terms
Chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia are driven by BCR-ABL, an abnormal tyrosine kinase that tells white blood cell precursors to keep multiplying. Ponatinib is taken by mouth and blocks BCR-ABL, including the T315I mutation that makes leukemia resistant to other kinase inhibitors. It also inhibits several other kinases involved in blood vessel formation and cell growth. Blocking these signals stops or slows leukemia cell proliferation and can induce cell death.
In depth
Ponatinib hydrochloride is an orally bioavailable, multitargeted receptor tyrosine kinase inhibitor. It inhibits unmutated and all mutated forms of BCR-ABL, including T315I, the highly drug-resistant missense mutation of BCR-ABL encoded by the Philadelphia chromosome. Ponatinib also inhibits other tyrosine kinases, including vascular endothelial growth factor receptors (VEGFRs), fibroblast growth factor receptors (FGFRs), the TIE2 receptor, and FMS-related tyrosine kinase receptor-3 (Flt3). This breadth of inhibition can suppress cellular proliferation and angiogenesis and induce cell death, supporting use across chronic, accelerated, and blast phase CML and Ph+ ALL.
See it in motion
A schematic animation of the mechanism — simplified for clarity, not drawn to scale.
Ponatinib is shaped to reach around the lock
- Philadelphia chromosome-positive leukemia runs on a stuck accelerator, the BCR-ABL protein.
- Some cancers mutate the accelerator's lock, the T315I change, so earlier drugs no longer fit.
- Ponatinib is taken by mouth and blocks BCR-ABL, including the T315I mutation that makes leukemia resistant to other kinase inhibitors.
- This breadth of inhibition can suppress cellular proliferation and angiogenesis and induce cell death, supporting use across chronic, accelerated, and blast phase CML and Ph+ ALL.
Target: BCR-ABL fusion tyrosine kinase, including the T315I mutant
The abnormal protein encoded by the Philadelphia chromosome that drives leukemia cell multiplication; the T315I change blocks most earlier kinase inhibitors, but ponatinib still fits and shuts it down.
Approved uses
Approved uses differ by country and change over time. Always follow your local prescribing information.
Approved uses in United States
FDA- In combination with chemotherapy, for newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL)
- As monotherapy, for Ph+ ALL for whom no other kinase inhibitors are indicated, or for T315I-positive Ph+ ALL
- For chronic phase chronic myeloid leukemia (CML) with resistance or intolerance to at least two prior kinase inhibitors
- For accelerated phase or blast phase CML for whom no other kinase inhibitors are indicated
- For T315I-positive CML (chronic phase, accelerated phase, or blast phase)
Approved uses in European Union
EMA- As monotherapy, for adults with chronic phase, accelerated phase, or blast phase chronic myeloid leukemia who are resistant to dasatinib or nilotinib, who are intolerant to dasatinib or nilotinib and for whom subsequent treatment with imatinib is not clinically appropriate, or who have the T315I mutation
- For Philadelphia chromosome-positive acute lymphoblastic leukemia in adults who are resistant to dasatinib, who are intolerant to dasatinib and for whom subsequent treatment with imatinib is not clinically appropriate, or who have the T315I mutation
- In combination with reduced-intensity chemotherapy, for adults with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia
- As monotherapy, for pediatric patients 6 years of age or older with chronic phase chronic myeloid leukemia who are resistant to dasatinib or nilotinib, who are intolerant to dasatinib or nilotinib and for whom subsequent treatment with imatinib is not clinically appropriate, or who have the T315I mutation
Official sources
The statements on this page trace back to these records.
- Iclusig (ponatinib) — Summary of product characteristics and package leaflet, English version
European Medicines Agency
- DailyMed: ICLUSIG (ponatinib) official US label
U.S. National Library of Medicine, DailyMed
- U.S. Food and Drug Administration: ponatinib prescribing information
U.S. Food and Drug Administration
- MedlinePlus: ponatinib
MedlinePlus, U.S. National Library of Medicine
- National Cancer Institute: ponatinib hydrochloride
National Cancer Institute
This page explains how the medicine works — it isn’t the patient leaflet. For anything that applies to you, read the leaflet that came with your medicine or ask your pharmacist.
MedUnfold provides educational content and is not medical advice. Always follow your local prescribing information and healthcare professional.